132 related articles for article (PubMed ID: 33537135)
41. Tigecycline susceptibility and the role of efflux pumps in tigecycline resistance in KPC-producing Klebsiella pneumoniae.
He F; Fu Y; Chen Q; Ruan Z; Hua X; Zhou H; Yu Y
PLoS One; 2015; 10(3):e0119064. PubMed ID: 25734903
[TBL] [Abstract][Full Text] [Related]
42. Molecular characterization of carbapenem-resistant
Yan WJ; Jing N; Wang SM; Xu JH; Yuan YH; Zhang Q; Li AL; Chen LH; Zhang JF; Ma B; Ma Q; Li Y
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33587030
[No Abstract] [Full Text] [Related]
43. Tigecycline activity against metallo-β-lactamase-producing bacteria.
Kumar S; Bandyopadhyay M; Mondal S; Pal N; Ghosh T; Bandyopadhyay M; Banerjee P
Avicenna J Med; 2013 Oct; 3(4):92-6. PubMed ID: 24327967
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
45. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
[TBL] [Abstract][Full Text] [Related]
46. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
[TBL] [Abstract][Full Text] [Related]
47. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.
Naesens R; Ursi JP; Van Schaeren J; Jeurissen A
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):381-4. PubMed ID: 18802728
[TBL] [Abstract][Full Text] [Related]
48. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
49. Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections.
Santimaleeworagun W; Hemapanpairoa J; Changpradub D; Thunyaharn S
Infect Chemother; 2020 Sep; 52(3):345-351. PubMed ID: 32989939
[TBL] [Abstract][Full Text] [Related]
50. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
[TBL] [Abstract][Full Text] [Related]
51. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
Karlowsky JA; Biedenbach DJ; Kazmierczak KM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
[TBL] [Abstract][Full Text] [Related]
52. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
Farrell DJ; Flamm RK; Sader HS; Jones RN
Antimicrob Agents Chemother; 2013 Dec; 57(12):6305-10. PubMed ID: 24100499
[TBL] [Abstract][Full Text] [Related]
53. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
[TBL] [Abstract][Full Text] [Related]
54. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
[TBL] [Abstract][Full Text] [Related]
55. Comparative Minimal Inhibitory and Mutant Prevention Concentration of Eight Antimicrobial Agents Against
Yang F; Chen P; Wang H; Xing X; Wang S; Ishaq HM; Liao W
Microb Drug Resist; 2022 Feb; 28(2):229-235. PubMed ID: 34851749
[No Abstract] [Full Text] [Related]
56. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
[TBL] [Abstract][Full Text] [Related]
57. Susceptibility of multi-resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution.
Tan TY; Ng LS
Ann Acad Med Singap; 2007 Oct; 36(10):807-10. PubMed ID: 17987230
[TBL] [Abstract][Full Text] [Related]
58. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.
Tärnberg M; Nilsson LE; Dowzicky MJ
Int J Infect Dis; 2016 Aug; 49():141-8. PubMed ID: 27343986
[TBL] [Abstract][Full Text] [Related]
59. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
Bradford PA; Weaver-Sands DT; Petersen PJ
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S315-32. PubMed ID: 16080070
[TBL] [Abstract][Full Text] [Related]
60. Over expression of AdeABC and AcrAB-TolC efflux systems confers tigecycline resistance in clinical isolates of Acinetobacter baumannii and Klebsiella pneumoniae.
Yuhan Y; Ziyun Y; Yongbo Z; Fuqiang L; Qinghua Z
Rev Soc Bras Med Trop; 2016 Apr; 49(2):165-71. PubMed ID: 27192584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
